3 Sales Growth Picks to Bet on for Steady Returns in 2026

Against a backdrop of lingering 2025 themes—AI optimism, Federal Reserve policy outlook, geopolitical tensions and tariff risks—Zacks screens for companies with superior revenue momentum and strong cash positions to identify buy candidates. Using filters (5-year sales growth > industry, cash flow > $500M, P/S < industry, positive four-week F1 sales estimate revisions, average 5-year operating margin >5%, ROE >5%, Zacks Rank ≤2), it highlights MKS Inc. (MKSI) with expected 2026 sales growth of 6.9%, Ameren Corporation (AEE) at 7.2%, and ONE Gas, Inc. (OGS) at 5% as stocks worth buying.

Analysis

Market structure: AI-driven semiconductor and photonics capex is a clear winner — niche process-control vendors (MKSI) gain pricing power and order lead-times while commodity equipment and OEMs tied to cyclical consumer demand are vulnerable. Regulated utilities (AEE, OGS) are defensive winners for income and stability given predictable rate-case pass-throughs, but their upside is capped by regulation. Supply/demand signals point to tighter lead times for high-end tools over the next 6–18 months and a modestly tighter natural gas supply curve that can lift utility cash flows if prices normalize above $3.50/MMBtu.

Risk assessment: Tail risks include abrupt export controls on high-end tools, a sharp Fed-induced recession cutting capex 20–40% (12–18 months), or a utility rate-case setback eroding 1H revs. Near-term catalysts are quarterly order books, Commerce/DOE policy decisions, and US 10yr yield moves; medium-term (3–12 months) drivers are book-to-bill and regulatory filings. Hidden dependencies: MKSI exposure is leveraged to China/Aisan capex trends and AEE/OGS depend on weather and regulatory lag.

Trade implications: Establish concentrated, sized positions: tactical 1–3% long MKSI to play AI capex recovery (target +30–40% in 6–12 months if book-to-bill >1.0) and 3–5% combined AEE/OGS for income and duration exposure, using covered calls to harvest yield. Consider a relative trade (long MKSI, short LRCX) to express niche-tool outperformance while hedging broad etch cyclicality; use options (buy MKSI 12–24 month calls or Jan 2027 LEAPs) to asymmetric payoff if volatility cheapens.

Contrarian angles: Consensus underestimates how export controls could accelerate domestic winners — MKSI could gain share even if overall capex stalls. Conversely, utilities are widely treated as bond proxies; a 50–100bp fall in real yields would materially re-rate AEE/OGS beyond dividend support. Watch book-to-bill, regulator outcomes, and US-China trade policy as binary events that can quickly flip these trades.

Key Decisions for Investors

• Initiate a 1–2% long position in MKSI within 2–8 weeks; set a tactical target of +35–40% in 6–12 months and a hard stop-loss at -20%; add to 3% only if sequential order backlog growth >10% or book-to-bill >1.0.
• Establish a 3–5% combined allocation to AEE (60%) and OGS (40%) as a 2–3 year income/defensive sleeve; write 30–60 day covered calls when implied vol >20% to generate 2–4% annualized income; trim 50% if utility spreads widen by >150bp vs Treasuries or a rate-case is denied.
• Enter a 1% long MKSI / 1% short LRCX pair trade for 3–12 months to express relative strength in niche process-control vs broad etch exposure; unwind if relative returns diverge >15% adverse or if MKSI fails to report book-to-bill improvement in two quarters.
• Purchasing asymmetric upside: allocate 0.5–1% of portfolio to MKSI Jan 2027 LEAPs (or nearest long-dated calls) as convex exposure to an AI-driven capex cycle; hedge by selling covered calls on AEE/OGS to fund cost.
• Reassess all positions within 30 days of the next Fed decision, within 60 days of MKSI quarterly order updates, and within 90 days of major utility rate-case rulings; reduce exposures by 30–50% on negative catalyst realization.